About Medigene
Medigene is a publicly listed company based in Planegg (Germany) founded in 1994. T cell immunotherapies for haematological malignancies are developed. It operates on a HealthTech model. The company has 114 employees. Medigene has completed 1 acquisition, including Trianta Longo. Medigene offers products and services including MDG1015 and TCR Technology Platform. Its focus areas include Biotechnology and Immunotherapy. Its legal entity is Medigene AG.
Company details
Medigene AG is engaged in the development of next-generation T-cell receptor (TCR) therapies for precision immunotherapies targeting various cancer types. The companys end-to-end platform is utilized to create optimal affinity TCRs applicable across multiple modalities, including TCR-T cell engagers, TCR-natural killer cell therapies, and TCR-T therapies. Solutions are developed to offer innovative and complementary treatment options within the healthcare and biotechnology sectors.
- Headquarters Planegg, Germany
- Employees 114
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website medigene.com
- Social LinkedIn X
- Legal Name Medigene Ag
- Latest Funding Round$6.35M (USD), Post-IPO
May 2024
- Investors
- Employee Count114
- Investments & Acquisitions
Products & Services of Medigene
Medigene offers a comprehensive portfolio of products and services, including MDG1015 and TCR Technology Platform.
A TCR-T therapy targeting NY-ESO-1/LAGE-1a for cancer.
Platform for generating TCRs for cancer treatment modalities.
Funding Insights of Medigene
- Total Rounds 4
- Last Round Post-IPO — $6.35M
- First Round $19.98M
(Mar 2004)
- Investors Count 1
All 4 funding rounds of Medigene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $6.35M | Post-IPO | – | – | – |
| May 2018 | $37.87M | Post-IPO | – | – | – |
| Jun 2012 | $17.68M | Post-IPO | – | – | |
| Mar 2004 | $19.98M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Medigene
Medigene has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States |
Investor details for Medigene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Medigene
24 people are tracked at Medigene (6 in leadership, 5 in board & advisors, 13 in team); the tracked headcount is 114.
| Name | Role | Group |
|---|---|---|
Selwyn Ho | CEO | Leadership |
Dolores J. Schendel | Chief Scientific Officer | Leadership |
Giulia Longinotti | Senior Director TCR Discovery Platform | Leadership |
Fotini Vogiatzi | Executive Assistant, CEO | Leadership |
Dr. Kathrin Davari | Vice President Portfolio Management And Strategy | Leadership |
Mario Catarinella | Senior Director | Leadership |
Anthony Man | Board Member | Board & advisors |
Gerd Zettlmeissl | Chairman | Board & advisors |
Antoinette Hiebeler-Hasner | Deputy Chair | Board & advisors |
Frank Mathias | Board Member | Board & advisors |
Ronald Scott | Board Member | Board & advisors |
Tânia Santos | Scientist | Team |
Joanna Madej | Research Associate | Team |
Christopher Plehn | Research Associate | Team |
Steffen Heuer | Senior Research Associate | Team |
Melanie Salvermoser | Senior Scientist - Team Leader | Team |
Dirk Delaere | Senior Manager Accounting | Team |
Gisela Engelke | Vorstandsassistenz | Team |
Kerstin Schwarzenlander | CMC Manager | Team |
Dr. Wiebe Mohr | Senior Scientist / Labhead | Team |
4 more people are available in the full profile.
Complete people profiles for Medigene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Medigene
Medigene has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Trianta Longo.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of insurance brokerage services | triantalongo.com | Thornhill, Canada | 2014 | Jan 2014 | $13.5M |
Complete acquisition details for Medigene
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Medigene
5 dated milestones of Medigene across 30 years, from founding to its latest funding, stage changes and deals.
- Founded Medigene is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $20.0M.
- Acquisition Acquires Trianta Longo.
- Funding Latest funding round, Post-IPO, of $6.4M.
Web traffic of Medigene
The website of Medigene (medigene.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 10.4% vs previous month
Websites whose visitors overlap most with Medigene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biosphings.com | 100% | View details | |||
topotarget.com | topotarget.com | 99% | – | ||
medigenomix.de | medigenomix.de | 72% | – | ||
cisc.twbbs.org | cisc.twbbs.org | 62% | – | ||
cidpusa.org | cidpusa.org | 62% | #10,513,187 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Medigene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medigene
Complete news archive for Medigene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medigene
Medigene was founded in 1994 and raised its 1st funding round 10 years after it was founded.
Medigene is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Medigene has 114 employees.
Medigene AG is engaged in the development of next-generation T-cell receptor (TCR) therapies for precision immunotherapies targeting various cancer types. The companys end-to-end platform is utilized to create optimal affinity TCRs applicable across multiple modalities, including TCR-T cell engagers, TCR-natural killer cell therapies, and TCR-T therapies. Solutions are developed to offer innovative and complementary treatment options within the healthcare and biotechnology sectors.
Medigene offers MDG1015 and TCR Technology Platform.
Medigene has made 1 acquisition, including Trianta Longo.
Medigene has 1 investor. Key investors include HealthCare Royalty Partners.
Medigene operates through Medigene Ag.